Alliance webinar showcases latest cancer research from 2026 ASCO Meeting

The Alliance for Clinical Trials in Oncology will host a free public webinar on October 1, 2026, highlighting selected findings from Alliance and Alliance Foundation Trials studies presented at the 2026 American Society for Clinical Oncology (ASCO) Annual Meeting. The 60-minute event will feature four clinical investigators discussing research involving breast, lung and prostate cancers, together with patient representatives from the Alliance Patient Alliance Committee. According to the Alliance’s meeting announcement, the panel will examine the significance of the studies for people living with cancer and their loved ones. The announcement identifies the event as a presentation of research already presented at the 2026 ASCO Meeting; it does not provide numerical results from the four featured studies.

Jennifer Ligibel, MD, of Dana-Farber Cancer Institute, will present results from Alliance A011401, also identified as the Breast Cancer Weight Loss Study, or BWEL. Her scheduled oral abstract concerns the effect of a weight-loss intervention on quality of life and symptoms in women with breast cancer. The study is therefore presented as an intervention trial with quality-of-life and symptom outcomes, rather than simply as an observational analysis of weight and cancer outcomes. The announcement provides the abstract title as “Effect of a weight loss intervention (WLI) on quality of life (QOL) and symptoms in women with breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial.” It does not disclose the number of participants, intervention details, follow-up period, effect estimates or statistical uncertainty for those outcomes.

Ramaswamy Govindan, MD, of WashU Medicine, will discuss Alliance A081105, including the trial’s final overall-survival results. The study evaluated whether adding the targeted cancer therapy erlotinib to observation could improve outcomes in people with non-small cell lung cancer after surgical removal of their tumors. Its population was defined by complete resection and EGFR-mutant disease, making the trial a study of postoperative erlotinib versus observation in a molecularly selected group. The abstract is titled “Adjuvant erlotinib versus observation after complete resection of EGFR-mutant NSCLC: Final overall survival results of Alliance A081105.” The release identifies the presentation as the final overall-survival analysis but does not report the survival estimates, hazard ratio, confidence interval, sample size or other numerical findings.

Elizabeth Wulff, MD, of the University of Kansas Medical Center, will present findings from AFT47/ARACOG, a randomized clinical trial comparing the cognitive effects of the hormone therapies darolutamide and enzalutamide in men with advanced prostate cancer. The announced abstract title is “Cognitive effects of darolutamide vs enzalutamide: Results of ARACOG (AFT-47), a randomized clinical trial from the Alliance for Clinical Trials in Oncology.” In this study, cognition is the stated focus of the treatment comparison. The announcement does not supply the number of men assessed, the duration of treatment or follow-up, cognitive-test results, adverse-event data or the magnitude of any difference between the drugs. Those details are not supplied in the release and therefore cannot be characterized here as established results.

Stephanie Berg, DO, of Dana-Farber Cancer Center, will discuss Alliance A032101, the A-DREAM study examining whether some men with advanced prostate cancer can take a break from hormone therapy. The announcement describes A-DREAM as a Phase III trial evaluating interruption of androgen-deprivation therapy in selected men with metastatic hormone-sensitive prostate cancer who responded exceptionally to an androgen-receptor pathway inhibitor. The listed presentation is titled “A phase 2 trial of androgen deprivation therapy interruption in patients responding exceptionally to androgen receptor pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM / Alliance A032101).” The source thus contains both a Phase III description in its general announcement and a phase 2 designation in the abstract title. That discrepancy cannot be resolved from the supplied material and should not be interpreted here as a conclusion about the trial’s design or results.

Patient representatives from the Patient Alliance Committee will also participate in the webinar. The announcement says they will comment on the importance of each trial and provide insight into the patient perspective. The four studies address distinct clinical questions: whether a weight-loss intervention affected quality of life and symptoms in women with breast cancer; whether postoperative erlotinib could improve outcomes after resection of EGFR-mutant non-small cell lung cancer; how darolutamide and enzalutamide differed in cognitive effects among men with advanced prostate cancer; and whether androgen-deprivation therapy could be interrupted in a selected group of men with metastatic hormone-sensitive prostate cancer. The release does not attribute any specific efficacy or safety result to the patient representatives, nor does it claim that their participation altered a trial endpoint or conclusion.

“We are excited to showcase the high-profile research findings that several Alliance researchers presented at the 2026 ASCO Meeting,” said Evanthia Galanis, MD, DSc, Group Chair of the Alliance and Sandra J. Schulze Professor of Novel Therapeutics and Professor of Oncology at the Mayo Clinic. In the same announcement, Galanis described the Alliance’s ability to advance discoveries and make meaningful improvements in cancer care as supported by National Cancer Institute funding and industry collaborations. This statement describes the Alliance’s stated research model and its leadership’s view of the organization’s work. It does not establish that any particular industry collaboration funded the four studies featured in the webinar, nor does it quantify the contribution of NCI or industry support to the individual results.

Olwen Hahn, MD, Director and Principal Investigator of the Alliance Central Protocol Operations Program and Associate Professor of Medicine at the University of Chicago Medical Center, said clinical trials conducted by Alliance researchers have meaningfully shaped cancer care and have often resulted in new standards of care and U.S. Food and Drug Administration approval of new treatments. Hahn also said the investigators would explain how the latest research results are affecting cancer care and that patient representatives would help explain the significance of the findings for people living with cancer and their loved ones. This is a broad statement about the Alliance’s record. It should not be read as an announcement of a new regulatory decision, a new clinical standard or a documented change in practice arising specifically from BWEL, A081105, ARACOG or A-DREAM. The release does not provide those study-level results or implementation data.

Registration for the webinar is open, and the event is free and available to the public. The Alliance describes itself as a national clinical-trials network that brings together more than 26,000 cancer specialists at 112 main institutions and 1,400 affiliates across the United States and Canada. It is part of the National Clinical Trials Network and a leading research base for the NCI Community Oncology Research Program. The Alliance reports that more than 40,000 participants have taken part in its studies and that its biospecimen repository now contains more than 1.5 million samples collected over 30 years. These are organizational figures reported in the announcement. The event notice does not provide a participant count for the October 1 webinar or establish how many people attended the featured studies.

Alliance Foundation Trials, LLC, develops and conducts cancer clinical trials in collaboration with Alliance investigators, the institutional member network, research collaborators and non-NCI funding sources. The organization says its current studies are funded by industry collaborators and the Patient-Centered Outcomes Research Institute. The October 1 webinar will cover selected research from both Alliance and Alliance Foundation Trials, including the four investigator-led presentations and the participation of the Patient Alliance Committee. Although the release characterizes the program as a way to explain how the latest results are affecting cancer care, it supplies no numerical outcomes for the featured abstracts, comparative effect sizes, safety rates or recommendations for patients. The supported conclusion is therefore that a public scientific webinar is scheduled to present and discuss selected clinical-trial findings from the 2026 ASCO Annual Meeting across breast, lung and prostate cancers.

Subject of Research: A public webinar on Alliance cancer-trial findings in breast, lung and prostate cancers presented at the 2026 ASCO Annual Meeting.

Article Title: Alliance webinar showcases latest cancer research from 2026 ASCO Meeting

Article References: Alliance webinar showcases latest cancer research from 2026 ASCO Meeting. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: Alliance for Clinical Trials in Oncology, 2026 ASCO Annual Meeting, clinical trials, breast cancer, lung cancer, prostate cancer, weight-loss intervention, erlotinib, hormone therapy, patient perspectives, Alliance, webinar